Item Posts Archive - Page 48 of 1770 - Medivizor
Navigation Menu

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Posted by on Sep 30, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) given after surgery in patients with stage II melanoma. The data showed that pembrolizumab given after surgery for up to 1 year significantly reduced the risk of cancer recurrence or death in these patients. Some background Melanoma is one of the most...

Read More

Comparing the effectiveness and safety of single-dose versus multiple-dose GnRH agonist for luteal-phase support in patients undergoing IVF/ICSI cycles.

Comparing the effectiveness and safety of single-dose versus multiple-dose GnRH agonist for luteal-phase support in patients undergoing IVF/ICSI cycles.

Posted by on Sep 29, 2022 in Infertility | 0 comments

In a nutshell This study compared the effectiveness and safety of single-dose (DS) versus multiple-dose (MD) GnRH agonist protocol for luteal phase support in patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. The data showed that the MD protocol was more effective in increasing the live birth and...

Read More

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Posted by on Sep 27, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...

Read More

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and ibrutinib (Imbruvica) could be combined for the treatment of patients with chronic lymphocytic leukemia (CLL).   This study concluded that adding anti-CD19 CAR T-cell therapy (CART-19) to ibrutinib treatment in these patients...

Read More

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to compare salvage intensive chemotherapy (IC) and a venetoclax (Venclexta; VEN)-combined low-intensity regimen in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study concluded that the VEN-combined regimen provided similar responses and survival rates when compared to...

Read More